Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Allakos Inc (ALLK)

Allakos Inc (ALLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share GlobeNewswire - Wed Apr 2, 2025

SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing...

ALLK : 0.3291 (-0.06%)
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share GlobeNewswire - Wed Apr 2, 2025

ALLK : 0.3291 (-0.06%)
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results GlobeNewswire - Wed Mar 12, 2025

ALLK : 0.3291 (-0.06%)
Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade Stocktwits - Mon Jan 27, 2025

The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.

ALLK : 0.3291 (-0.06%)
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring GlobeNewswire - Mon Jan 27, 2025

ALLK : 0.3291 (-0.06%)
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results GlobeNewswire - Wed Nov 6, 2024

ALLK : 0.3291 (-0.06%)
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers GlobeNewswire - Thu Oct 10, 2024

ALLK : 0.3291 (-0.06%)
Why Shares of Allakos Are Up Wednesday Motley Fool - Wed Sep 27, 2023

The stock is bouncing back from a recent 52-week low.

ALLK : 0.3291 (-0.06%)
Why Allakos Stock Skyrocketed Nearly 9% Higher Today Motley Fool - Fri May 12, 2023

The company is poised to report a critical set of clinical data in the coming months.

ALLK : 0.3291 (-0.06%)
Why Allakos Stock Was Heating Up Today Motley Fool - Tue Mar 7, 2023

A notable analyst upgrade had investors piling into this clinical-stage biotech stock today.

ALLK : 0.3291 (-0.06%)
PIPR : 74.53 (+0.05%)

Barchart Exclusives

If You Have Some ‘Silly’ Money, United Microelectronics (UMC) Stock Is Worth a Look Barchart - 19 minutes ago
While Wall Street remains pensive about the long-term trajectory of UMC stock, there is a possible momentum case to be made. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.